Госпитальные инфекции, вызванные Pseudomonas aeruginosa. Распространение и клиническое значение антибиотикорезистентности

Кафедра микробиологии и клинической химиотерапии Российской медицинской академии последипломного образования, Государственный научный центр по антибиотикам, Москва.

В начало...

ЛИТЕРАТУРА

2. Gillardi G.L. Pseudomonas and related genera. In: Manual of clinical microbiology. 5th ed. Balows A., ed. Washington DC. 1991; 429-441.

3. Palleroni N.J. Family I: Pseudomonadaceae. In: Bergey's manual of systematic bacteriology. Kraig N.R., Holt J.G. (Eds.). Baltimore 1984; 1: 141-219.

4. Stock J.B., Ninfa A.J., Stock A.M. Protein phosphorylation and regulation of adaptive response in bacteria. Microbiol Rev 1989; 53: 450-490.

5. Frank D.W., Iglewski B.H. Cloning and sequence analysis of a transregulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa. J Bacteriol 1991; 173: 6460-6468.

6. Hobbs M., Collie E.S.R., Free P.D. et al. PilS and PilR, a two-component transcriptional regulatory system controlling expression of type 4 fimbriae in Pseudomonas aeruginosa. Mol Microbiol 1993; 7: 669- 682.

7. Fuqua W.C., Winans S.C., Greenberg E. P. Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J Bacteriol 1994; 176: 269-275.

8. Pesci E.C., Inglewski B.H. The chain of command in Pseudomonas quorum sensing. Trends Microbiol 1997; 24: 132-134.

9. Yahr T.L., Mende-Mueller L.M., Friese M.B., Frank D.W. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179: 7165-7168.

10. Kadurugamuwa J.L, Beveridge T.J. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40: 615-621.

11. Talon D., Mulin B., Rouget C. et al. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa. Amer J Resp Crit Care Med 1998; 157: 978-984.

12. Fagon J.Y, Chastre J, Domart Y. et. al. Mortality due to ventilator-associated pneumonia or colonisation with Pseudomonas or Acinetobacter species: Assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23: 538-542.

13. Falagas M.E., Barefoot L., Griffith J. et. al. Risk factors leading to clinical failure in the treatment of intraabdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-921.

14. Fluit A. C., Jones M. E., Schmitz F.-J. et. al. Antimicrobial Resistance among clinical blood isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Therapy. 38th Interscience Conference on antimicrobial agents and chemotherapy. Sept. 24-27, 1998, San Diego 1998; Abst. E-86.

15. Baltch A.L., Griffin P.E. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci 1977; 274: 119-120.

16. Bodey G.P., Jadeja L., Elting L. Pseudomonas bacteremia: Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621-1629.

17. McKendrick M.W., Geddes A.M. Pseudomonas septicaemia in general hospital: seven years' experience. Quart J Med 1981; 199: 331-344.

18. Lechi A., Arosio E., Pancera P. et al. Pseudomonas septicaemia. A review of 60 cases observed in a university hospital. J Hosp Infect 1984; 5: 29-37.

19. Gallaghar P.G., Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980 - 1984. Rev Infect Dis 1989; 11: 846-852.

20. Hilf M., Yu V.L., Zuravleff J.J. et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlation in a prospective study of 200 patients. Am J Med 1989; 87: 540-546.

21. Mallolas J., Gatell J.M., Miro J.M. et al. Prognostic factors for Pseudomonas aeruginosa bacteremia [Letter]. Am J Med 1991; 90: 134-134.

22. Vidal F., Mensa J., Almela M. et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence on antibiotic treatment. Analysis of 198 episodes. Arch Intern Med 1996; 156: 2121-2126.

23. Laughlin T.J., Armstrong D.G., Caporusso J., Lavery S.A. Soft tissue and bone infection from puncture wounds in children. West Med J 1997; 166: 126-128.

24. Pedersen H.B., Rosborg J. Necrotizing external otitis: aminoglycoside and beta-lactam treatment combined with surgical treatment. Clin Otolaryngol 1997; 22: 271-274.

25. Yoshida E., Nakae T. Identification of porin in the outer membrane of Pa that forms small diffusion pores. J Biol Chem 1989; 264: 6297- 6301.

26. Nikaido H., Nikaido K., Harayama S. Identification and characterization of porins in Pseudomonas aeruginosa. J Biol Chem 1991; 266: 770-779.

27. Bellido F., Martin N.L., Siehnell R.J., Hancock R.E.W. Reevaluation, using intact cells, of the exclusion limit and role of porin OprF in Pseudomonas aeruginosa outer membrane permeability. J Bacteriol 1992; 174: 5196-5203.

28. Nikaido H., Hancock R.E.W. Outer membrane permeability in Pseudomonas aeruginosa. In: The bacteria. Sokatch J. ed. Orlando 1986; 10: 145-193.

29. Huang H., Hancock R.E.W. Genetic definition of the substrate selectivity of Pseudomonas aeruginosa outer membrane porin protein Opr D. J Bacteriol 1993; 175: 7793-7800.

30. Trias J., Nikaido H. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for amino acids and peptides. J Biol Chem 1990; 265: 15680-15684.

31. Watanabe N.A. Newer antipseudomonal cephalosporines. J Chemother 1996; 8: Suppl. 2: 48-56.

32. Livermore D.M. -lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995 ; 8: 557 - 584.

33. Nikaido H., Thanassi D.G. Penetration of lipophilic agents with multiple protonation sites into bacteria cells; tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993; 37: 1393-1399.

34. Poole K., Krebes K., McNally C., Neshat S. Multiple antibiotics resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operone. J Bacteriol 1993; 175: 7363-7372.

35. Ednie L.M., Jacobs M.R., Appelbaum P.C. Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Antimicrob Agents Chemother 1998; 42: 1269-1273.

36. Srikumar R., Li X. Z., Poole K. Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa. J Bacteriol 1997; 179: 24: 7875-7881.

37. Hancock R.E.W., Bell A. Antibiotic uptake in Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1988; 7: 713-720.

38. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.

39. Senda K., Arakawa Y., Nakashima K. et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother 1966; 40: 349-353.

40. Lee K., Chong Y., Shin H.B., Yong D. Rapid increase of imipenem-hydrolyzing Pseudomonas aeruginosa in a Korean Hospital. 38th Intersci Conf on Antimicrob Agents Chemother Sept. 24-27, 1998. San Diego1998; Abst. E-85.

41. Hawkey P.M., Chanawong A., Lulitanond A. et al. SHV-5 extended-spectrum -lactamase from Pseudomonas aeruginosa in Thailand. Ibid. Abst. C-174a.

42. Edwards J.R. Meropenem: a microbiological overview. J Antimicrob. Chemother 1995; 36: Suppl. A, 1-17.

43. Ziha-Zarifi I., Llanes C., Kohler T., Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa-overexpressing the MexA-MexB-OprM-efflux system. 38th Interscience Conf. Antimicrob. Agents and Chemother Sept. 24-27, 1998, San Diego, California. Am Soc Microbiol 1998; Abst. C-128.

44. Kohler T., Michea-Hamzehpour M., Epp S.F., Pechere J-C. Carbapenem activity in Pseudomonas aeruginosa: respective contribution of OprD and efflux systems. Ibid; 1998; Abst. C-127.

45. Miller G.H. Nature and rate of aminoglycoside resistance mechanisms. Clin Drug Invest 1996; 12: Suppl. 1: 1-12.

46. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci 1995; 20: 156-160.

47. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and 4-quinolones. Microbiol Molec Biol Rev 1997; 61: 377-292.

48. Nakano M., Deguchi T., Kawamura T. et al. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2289-2291.

49. Kohler T, Micheahamzehpour M., Plesiat P., Kahr A.L., Pechere J.C. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Ibid: 2540-2543.

50. Lomovskaya O., Lee A., Mistry A. et al. Multidrug resistance pumps as important targets for antibacterial therapy. 38th Intersci Conf Antimicrob Agents Chemother Sept. 24-27 1998, San Diego. 1998; Abst. C-120.

51. National Committee for Clinical Laboratory Standards. (1997). Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4, 4th ed. NCCLS, Villanova, PA.

52. Troillet N, Samore M.H., Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 5: 1094-1098.

53. Pierard D., Emmerechts K., Lauwers S. Comparative in vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. J Antimicrob Chemother 1998; 41: 443-450.

54. Bonfiglio G., Laksai Y., Franceschini N. et al. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units. Chemotherapy 1998; 44: 305-312.

55. Iaconis J.P., Pitrin D.H., Sheikh W., Nadler H.L. Comparison of antibacterial activities of meropenem and six other antimicrobial agents against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1977; 24: Suppl. 2: 191-196.

56. Fernandes C., Pritchard R., Morris A., Benn R. In vitro evaluation of cefpirome: an Australian study of isolates from intensive care unit and hematology/oncology patients. Diagn Microbiol Infect Dis 1998; 30: 493-495.

57. Andriole V.T. Pseudomonas bacteremia: can antibiotic therapy improve survival? J Clin Lab Med 1979; 94: 196-200.

58. Weinstein R.J., Young L.S., Hewitt W.L. Comparison of methods for assessing in vitro antibiotics synergism against Pseudomonas and Serratia. J Clin Lab Med 1975; 86: 853-862.

59. Khakoo R.A., Kluge R.M. Effectiveness of carbenicillin and gentamicin in a rat model against infection with Pseudomonas aeruginosa resistant to gentamicin or gentamicin and carbenicillin. J Antimicrob Chemother 1979; 5: 53-59.

60. Baltch A.L., Smith R.P. Combination of antibiotics against Pseudomonas aeruginosa. Am J Med 1985; 79: Suppl. 1A: 8-16.

61. Bodey G.P., Feld R., Burgess M.A. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. Am J Med Sci 1976; 271: 179- 186.

62. Solberg С. O., Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: A randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995; 36: Suppl. A: 157-166.

63. Brun-Buisson C, Sollet J.P., Schweich H. et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomised controlled trial. Clin Infect Dis 1998; 26: 346-354.

64. Garau J, Blanquer J., Cobo L. et al. Prospective, randomised, multicenter study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16: 789-796.

65. Byrne S., Maddison J., Connor P. et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp infections in cystic fibrosis patients. J Antimicrob Chemother 1995; 36: Suppl. A: 135-143.

66. Siegman-Igra Y., Ravona R., Primerman H., Giladi M. Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Intern J Infect Dis 1998; 2: 211-215.

67. Leibovici L, Paul M., Poznanski O. et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study. Antimicrob Agents and Chemother 1997; 41: 5: 1127-1133.

68. Denhollander J.G., Horrevorts A.M., Vangoor M.L.P.J. et. al. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Ibid; 95-100.